ArticleFrontiers in cardiovascular medicine2026
The ApoB/ApoA-I ratio and the risk of in-stent restenosis following drug-eluting stent implantation in patients with coronary heart disease: a retrospective cohort study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The Apolipoprotein B/Apolipoprotein A-I (ApoB/ApoA-I) ratio has been strongly associated with the risk of cardiovascular disease. However, its association with in-stent restenosis (ISR) after drug-eluting stent (DES) implantation in patients with coronary heart disease (CHD) remains unclear. Methods: This retrospective study enrolled CHD patients who underwent follow-up coronary angiography 6-24 months after successful DES-based percutaneous coronary intervention (PCI). The ApoB/ApoA-I ratio was calculated, and participants were grouped by quartiles of the ratio. Multivariable logistic regression and restricted spline cubic (RCS) models assessed the association between the ApoB/ApoA-I ratio and ISR risk. Subgroup and sensitivity analyses were also conducted. Results: A total of 1,004 CHD patients (mean age 67.32 ± 10.63 years, 63.65% male) were included. 176 (17.5%) patients developed ISR over a median 12-month follow-up. The prevalence of ISR rose stepwise with increasing quartiles of the ApoB/ApoA-I ratio (5.6% vs. 11.2% vs. 20.3% vs. 32.6%, Conclusions: An elevated ApoB/ApoA-I ratio was significantly associated with an increased risk for ISR after DES-based PCI in CHD patients. Our findings suggested that the ApoB/ApoA-I ratio might serve as a useful predictor for ISR risk in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.